mAbxience Expands Biosimilar and CDMO Manufacturing Capacity

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, said that mAbxience will equip their state-of-the-art cGMP facility in León, Spain with an ABEC 4,000L Custom Single Run (CSR) Bioreactor. The system will be commissioned mid-2021 and will increase biosimilar and CDMO manufacturing capacity at the León site.

The 4,000L volume and performance comparable to stainless steel systems will enable mAbxience to improve flexibility, productivity and efficiency. The CSR bioreactor design also allows for seamless scale-up and transfer of cell culture processes, thereby reducing time to market for mAbxience’s products.

“mAbxience is dedicated to continuously expanding our global capacity and capability to guarantee the supply of our high-quality biopharmaceutical products and CDMO services,” said Emmanuelle Lepine, general manager, mAbxience. “ABEC’s CSR technology provides us the benefit of multi-product flexibility without compromising economies of scale.”

Scott Pickering, CEO, ABEC, said, “We are pleased mAbxience has chosen ABEC to support their ongoing efforts to bring life-saving biopharmaceutical drugs to the global market. With dozens of installations around the world, ABEC’s CSR bioreactors reflect our mission to provide the industry with the most productive and cost-effective solutions for biopharmaceutical manufacturing.”